We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful. The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or f ...

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for failing to disclose risks related to Nexplanon sales growth, which impacted investor expectations and stock performance [1][3]. Summary by Sections Lawsuit Details - The lawsuit represents purchasers of Organon securities from November 3, 2022, to April 30, 2025, alleging that the company did not disclose a higher risk of loss of exclusivity and price erosion for Nexplanon [1][3]. Investor Information - Investors who acquired Organon securities during the class period have until July 22, 2025, to seek appointment as lead plaintiff [2]. Financial Impact - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 to $0.02 per share, indicating a shift in capital allocation priorities towards deleveraging [4]. - Following this announcement, Organon’s stock price fell by $3.48, approximately 27%, from $12.93 to $9.45 per share [4].

Core Insights - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid commercial challenges and a class-action lawsuit [1][2][3] Group 1: Leadership Changes - CFO Jean-Marc Bellemin's resignation aligns with his executive employment agreement and comes at a critical time for the company [2] - The company has not yet appointed a successor for the CFO position, creating uncertainty as it faces market and legal challenges [2] Group 2: Commercial Performance - Iovance's flagship drug, Amtagvi, has significantly underperformed, leading to a downward revision of the company's full-year revenue projections [3][6] - The first-quarter sales figures for Amtagvi fell short of Wall Street expectations, prompting a downgrade from UBS [3] Group 3: Legal Challenges - Iovance is facing a class-action securities fraud lawsuit related to its claims about authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5] - The lawsuit alleges discrepancies between the company's public statements about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Group 4: Market Reaction - Following the disclosure of disappointing first-quarter results and revised revenue guidance, Iovance's stock price dropped over 44%, from $3.17 to $1.75 per share within a day [7]

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][2]. Group 1: Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Group 2: Financial Disclosures and Stock Impact - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - On October 17, 2024, Elevance reported Q3 2024 financial results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, and lowered EPS guidance for 2024 from $37.20 to $33.00, or 11.3% [5]. - Following the October announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].

Core Viewpoint - A securities class action lawsuit has been filed against Viatris Inc. for allegedly misleading investors during the Class Period from August 8, 2024, to February 26, 2025 [1][3]. Company Overview - Viatris is a healthcare company based in Canonsburg, PA, that provides medicines to one billion patients globally [2]. Legal Context - The lawsuit claims that Viatris misled investors by downplaying the consequences of a failed inspection at its Indore, India facility and a Warning Letter from the U.S. Food and Drug Administration [3]. - Investors who purchased Viatris securities during the Class Period have until June 3, 2025, to seek appointment as lead plaintiff [2]. Law Firm Background - Berger Montague, the law firm handling the case, has been involved in securities class action litigation since 1970 and has represented both individual and institutional investors [5].

Core Viewpoint - A securities class action lawsuit has been filed against Zynex, Inc. for alleged misconduct during the Class Period from March 13, 2023, to March 11, 2025 [1][2]. Company Overview - Zynex, Inc. is a medical device company based in Englewood, CO, specializing in electrotherapy devices for pain management and rehabilitation [2]. Allegations and Impact - A report published by medical journal STAT on June 4, 2024, accused Zynex of an "oversupplying scheme," where the company allegedly sent excessive supplies to patients to bill insurers for inflated amounts, leading to insurers removing Zynex from their networks [3]. - Following the publication of the report, Zynex's stock price dropped by $0.50 per share, or 5%, closing at $9.35 on June 4, 2024 [3]. Financial Performance - On March 11, 2025, Zynex reported a significant revenue shortfall for Q4 and the full year of 2024, attributing it to slower payments from certain payers, including a temporary suspension of payments from Tricare as they reviewed prior claims [4]. - The announcement of the revenue shortfall resulted in a drastic decline in Zynex's stock price, which fell by $3.59 per share, or 51%, closing at $3.41 on March 12, 2025 [4].

Core Points - A securities class action lawsuit has been filed against Fluence Energy, Inc. for the period from October 28, 2021, to February 10, 2025 [1][2] - The lawsuit follows a report from Blue Orca Capital revealing that Siemens had sued Fluence for misrepresentation, breach of contract, and fraud [2] - Following the news of the Siemens lawsuit, Fluence's stock price dropped over 13%, from $17.01 to $14.73 per share [3] - On February 10, 2025, Fluence reported a Q1 fiscal 2025 net loss of $57 million, with revenues down 49% year-over-year, and subsequently lowered revenue guidance [3] - The stock price fell further by $6.07, or more than 46%, from $13.07 to $7.00 per share on February 11, 2025 [4] Legal Context - Investors who purchased Fluence securities during the class period have until May 12, 2025, to seek appointment as lead plaintiff [2] - A lead plaintiff represents the interests of all class members in the litigation process [5] - Berger Montague has a long history in securities class action litigation, representing both individual and institutional investors [6]

Core Viewpoint - A securities class action lawsuit has been filed against Semtech Corporation for alleged issues related to its CopperEdge product sales during the specified class period from August 27, 2024, to February 7, 2025 [1][2]. Company Overview - Semtech Corporation is headquartered in Camarillo, California, and operates as a semiconductor, digital systems, and cloud connectivity service provider. The company's product portfolio includes CopperEdge products, which are utilized in active copper cables [2]. Recent Developments - On February 7, 2025, Semtech announced that CopperEdge sales would not meet expectations for fiscal year 2026, indicating that sales would be lower than the previously estimated floor case of $50 million due to customer feedback and necessary architectural changes [3]. - Following this announcement, Semtech's stock price experienced a significant decline, dropping by $16.91, or 31%, to close at $37.60 per share on February 10, 2025 [3]. Legal Context - Investors who purchased Semtech securities during the class period have until April 22, 2025, to seek appointment as lead plaintiff representatives in the class action lawsuit [2].